Liver and Bile

Hepatology. 2023;77(2):430–42

Demory A, Péron JM, Calderaro J, Selves J, Mokrane FZ, Amaddeo G, Paradis V, Ziol M, Sutter O, Blaise L, Ganne-Carrié N, Vilgrain V, Cauchy F, Zucman-Rossi J, Ronot M, Nault JC

Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation


Background and aims: The natural history of hepatocellular adenomas (HCAs) remains to be better described, especially in non-resected patients. The aim of this study was to identify the predictive factors of HCA evolution after estrogen-based contraception discontinuation.
Approach and results: The authors retrospectively included patients with a histological diagnosis of HCA from 3 centers, and collected clinical, radiological, and pathological data to identify predictive factors of radiological evolution per Response Evaluation Criteria in Solid Tumors, version 1.1, and occurrence of complications (bleeding, malignant transformation). They built a score using variables that modulate estrogen levels: body mass index and duration of estrogen-based contraception. An external cohort was used to validate this score. 183 patients were included in the cohort, including 161 women (89%) using estrogen-based contraception for a median of 12 years. 30% of patients had at least 1 HNF1A-inactivated HCA, 45.5% at least 1 inflammatory HCA, and 11% at least 1 HCA with activation of β-catenin (bHCA). 21 symptomatic bleedings (11%) and 11 malignant transformations (6%) occurred. Ages < 37 years old (p = 0.004) and HCA > 5 cm at imaging were independently associated with symptomatic bleeding (p = 0.003), whereas a bHCA was associated with malignant transformation (p < 0.001). After a median follow-up of 5 years, radiological regression was observed in 31%, stabilization in 47%, and progression in 22% of patients. Weight loss was associated with regression (p < 0.0001) and weight gain with progression (p = 0.02). The estrogen exposure score predicted radiological regression (odds ratio = 2.33; 95% confidence interval: 1.29–4.19; p = 0.005) with a linear relationship between the rate of estrogen exposure and the probability of regression. This result was confirmed in an external cohort of 72 female patients (p = 0.003).

Conclusion: Weight variation is strongly associated with radiological evolution after oral contraception discontinuation. A score of estrogen exposure, easily assessable in clinical practice at diagnosis, predicts regression of hepatocellular adenoma.

Prof. Dr. J.-C. Nault, Service d’Hépatologie, Hôpital Avicenne, Bobigny, France,
E-Mail: naultjc@gmail.com

DOI: DOI: 10.1002/hep.32734

Back to overview

this could be of interest:

Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors

Clin Gastroenterol Hepatol. 2023;21(2):406–14.e7

Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis

J Hepatol. 2023;78(1):114–22

More articles on the topic